Recent News

• 06.03.2026 - argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren’s Disease at EULAR 2026
• 05.28.2026 - argenx to Host Myositis R&D Webinar on June 23, 2026
• 05.27.2026 - argenx to Present at Upcoming Investor Conferences
• 05.08.2026 - argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
• 05.07.2026 - argenx Reports First Quarter 2026 Financial Results and Provides Business Update
• 05.06.2026 - argenx to Present at BofA Securities 2026 Health Care Conference
• 05.06.2026 - argenx Announces Results of Annual General Meeting and Board of Directors’ Appointment of Karen Massey as Chief Executive Officer
• 04.30.2026 - argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026
• 04.18.2026 - argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP
• 03.20.2026 - argenx announces Annual General Meeting of Shareholders on May 6, 2026

Recent Filings

• 05.11.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.11.2026 - EX-99.1 EX-99.1
• 05.07.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.07.2026 - EX-99.1 EX-99.1
• 05.06.2026 - EX-99.1 EX-99.1
• 05.06.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.06.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 04.20.2026 - EX-99.1 EX-99.1
• 04.20.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.20.2026 - EX-99.1 EX-99.1